Partnership for Assessment & Investigation of Neuropathic Pain - CIPN
Research type
Research Study
Full title
PAINSTORM: Partnership for Assessment and Investigation of NeuP: Studies Tracking Outcomes, Risks and Mechanisms - Dundee Chemotherapy Induced Peripheral Neuropathy (CIPN) study
IRAS ID
303039
Contact name
Lesley A Colvin
Contact email
Sponsor organisation
University of Dundee
Duration of Study in the UK
3 years, 5 months, 1 days
Research summary
Nerve or ‘neuropathic’ pain can occur when the nerves are damaged in some way. Unfortunately, many of the commonly used and effective chemotherapies for cancer treatment can damage nerves. People may develop Chemotherapy Induced Peripheral Neuropathy (CIPN) with pain and numbness, particularly in the hands and feet, during or after treatment.
CIPN can be so severe that the dose of chemotherapy needs to be reduced, or even stopped, during treatment. There are no effective preventive treatments, and limited treatment options if CIPN does develop. We do not understand why some people get neuropathic pain from chemotherapy whilst others do not, nor why is gets better in some people but not in others. Research that we have done has found that sometimes factors such as a person’s lifestyle, other diseases they have, past experiences they’ve had and family history (genetics), can make someone more likely to develop neuropathic pain. We want to understand what things make someone more or less likely to develop CIPN, and how it changes over time. This will then help us develop ways to reduce the risk of developing CIPN, as well as hopefully preventing and treating it.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
22/SC/0233
Date of REC Opinion
5 Sep 2022
REC opinion
Further Information Favourable Opinion